Comparative effectiveness and safety of eribulin in advanced or metastatic breast cancer: a systematic review and meta-analysis

被引：11

作者：

Tanni, Kaniz Afroz ^{[1
]}

Truong, Cong Bang ^{[1
]}

Johnson, Brandon S. ^{[2
]}

Qian, Jingjing ^{[1
]}

机构：

[1] Auburn Univ Harrison, Dept Hlth Outcomes Res & Policy, Sch Pharm, Auburn, AL 36849 USA

[2] East Alabama Med Ctr, Spencer Canc Ctr, Opelika, AL 36801 USA

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2021年 / 163卷

关键词：

Metastatic breast cancer; Comparative effectiveness; Adverse events; Chemotherapy; Eribulin; Systematic review; Meta-analysis; PHASE-II; POOLED ANALYSIS; CHEMOTHERAPY; MESYLATE; WOMEN; CAPECITABINE; PUBLICATION; MULTICENTER; GEMCITABINE; VINORELBINE;

D O I：

10.1016/j.critrevonc.2021.103375

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Eribulin is one of the few recommended chemotherapies for locally advanced breast cancer (LABC) or metastatic breast cancer (MBC). We systematically searched MEDLINE Ovid, Cochrane Library, IPA, CINAHL, Web of Science and ProQuest Dissertations for studies evaluating eribulin versus non-eribulin regimens in LABC/MBC till January 15, 2021. Primary effectiveness and safety outcomes were overall survival (OS) and adverse events (AE), respectively. Hazard ratios (HR) and relative risks (RR) with 95 % confidence intervals (CIs) were calculated using fixed or random-effects meta-analyses. Of 1183 publications identified, 13 studies were included in this review. Eribulin based therapy showed significantly increased OS [HR (95 % CI) = 0.77 (0.67-0.88)] compared to non-eribulin in both main and sensitivity analyses, as well as subgroup analyses according to receptor expression and line of therapy. Incidence of all-grade neutropenia was the only significant AE in eribulin than non-eribulin groups. Eribulin has a manageable toxicity profile and provides significant survival benefit in LABC/ MBC patients.

引用

页数：11

共 73 条

[1] Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9 [J].

Abraham, Jame ;

Robidoux, Andr ;

Tan, Antoinette R. ;

Limentani, Steven ;

Sturtz, Keren ;

Shalaby, Ibrahim ;

Alcorn, Hope ;

Buyse, Marc E. ;

Wolmark, Norman ;

Jacobs, Samuel A. .

BREAST CANCER RESEARCH AND TREATMENT, 2015, 152 (02) :399-405

[2]

[Anonymous], 2010, HALAVEN ERBULIN MESY

[3]

[Anonymous], 2020, Breast Cancer Facts & Figures

[4]

[Anonymous], 2020, Cochrane handbook for systematic reviews of interventions

[5]

[Anonymous], NEWCASTLE OTTAWA SCA

[6]

[Anonymous], CTCAE (Common Terminology Criteria for Adverse Events)

[7]

[Anonymous], WHO DRAFT GUIDELINES

[8]

ASCO, 2020, RES GUID BREAST CANC

[9] WHY THE COCHRANE RISK OF BIAS TOOL SHOULD INCLUDE FUNDING SOURCE AS A STANDARD ITEM [J].

Bero, Lisa A. .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (12)

[10] 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4) [J].

Cardoso, F. ;

Senkus, E. ;

Costa, A. ;

Papadopoulos, E. ;

Aapro, M. ;

Andre, F. ;

Harbeck, N. ;

Aguilar Lopez, B. ;

Barrios, C. H. ;

Bergh, J. ;

Biganzoli, L. ;

Boers-Doers, C. B. ;

Cardoso, M. J. ;

Carey, L. A. ;

Cortes, J. ;

Curigliano, G. ;

Dieras, V. ;

El Saghir, N. S. ;

Eniu, A. ;

Fallowfield, L. ;

Francis, P. A. ;

Gelmon, K. ;

Johnston, S. R. D. ;

Kaufmann, B. ;

Koppikar, S. ;

Krop, I. E. ;

Mayer, M. ;

Nakigudde, G. ;

Offersen, B. V. ;

Ohno, S. ;

Pagani, O. ;

Paluch-Shimon, S. ;

Penault-Llorca, F. ;

Prat, A. ;

Rugo, H. S. ;

Sledge, G. W. ;

Spence, D. ;

Thomssen, C. ;

Vorobiof, D. A. ;

Xu, B. ;

Norton, L. ;

Winer, E. P. .

ANNALS OF ONCOLOGY, 2018, 29 (08) :1634-1657

← 1 2 3 4 5 6 7 8 →